Related Experiment Video

Updated: Jun 4, 2026

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Targeting p27Kip1 protein: its relevance in the therapy of human cancer

Adriana Borriello1, Debora Bencivenga, Maria Criscuolo

  • 1Second University of Naples, Medical School, Department of Biochemistry and Biophysics F. Cedrangolo, Via De Crecchio 7, 80138 Naples, Italy.

Expert Opinion on Therapeutic Targets
|March 2, 2011
PubMed
Abstract

Insights

The protein p27 Kip1 regulates cell division and cancer progression. Targeting p27 Kip1 levels and location offers potential anticancer strategies, but risks must be considered.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • Cell division is regulated by cyclin-dependent kinases (CDKs).
  • p27 Kip1 is a key inhibitor of CDKs, controlling cell proliferation, differentiation, and apoptosis.
  • Altered p27 Kip1 levels and localization (nuclear vs. cytosolic) impact cancer prognosis.

Purpose of the Study:

  • To review the structure, metabolism, and alterations of p27 Kip1 in cancer.
  • To explore anticancer strategies targeting p27 Kip1.

Main Methods:

  • Literature review of p27 Kip1 structure and function.
  • Analysis of p27 Kip1 alterations in human malignancies.
  • Discussion of therapeutic strategies targeting p27 Kip1.

Main Results:

  • p27 Kip1's dual role: nuclear localization inhibits proliferation, while cytosolic localization promotes cytoskeleton remodeling and metastasis.
  • Downregulation or mislocalization of p27 Kip1 correlates with poor cancer prognosis.
  • Targeting p27 Kip1 presents a potential avenue for novel cancer therapies.

Conclusions:

  • Modulating p27 Kip1 levels and localization is a promising anticancer strategy.
  • Further research is needed to develop effective and safe p27 Kip1-targeting drugs.
  • Potential adverse effects of p27 Kip1 targeting warrant careful consideration.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...